Spijker J

Depression Expertise Center, Pro Persona Mental Health Care, Nijmegen, The Netherlands.

3 papers · 1 preprint · ORCID

ArticleKetamine

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Veraart JK, Smith-Apeldoorn SY, van der Meij A +3

Europe PMC2025
ArticleKetamine

Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.

Lima Constantino J, Godschalk M, van Dalfsen JH +5

Europe PMC2025
ArticleKetamine

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J +5

Europe PMC2024
PreprintKetamine

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension

Smith-Apeldoorn S, Veraart J, Kamphuis J +5

Europe PMC2023